Core Insights - ProFound Therapeutics has announced a four-year collaboration with Novartis to develop novel therapeutics for cardiovascular disease using its ProFoundry™ Platform [1][3] - The collaboration includes $25 million in upfront and near-term milestone payments, with potential downstream milestone payments of $750 million per target [1][3] Company Overview - ProFound Therapeutics focuses on discovering proteins within the expanded human proteome to develop first-in-class medicines for various diseases [4] - The ProFoundry™ Platform integrates multi-layered biological data and advanced computational tools to identify and validate novel proteins as drug targets [2][4] Collaboration Details - The partnership aims to leverage ProFound's capabilities in identifying novel proteins and Novartis' expertise in cardiovascular drug development [1][3] - The collaboration is expected to accelerate the discovery of new therapeutic targets and support the development of transformative therapies for cardiovascular diseases [3]

Nautilus Biotechnology (NAUT) Q1 2025 Earnings Call April 29, 2025 01:27 PM ET Speaker0 Good day, and thank you Speaker1 for standing by. Welcome to the Nautilus First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To ...

Nautilus Biotechnology (NAUT) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Ji-Yon Yi - Vice PresidentSujal Patel - Co-Founder, CEO & DirectorParag Mallick - Co-Founder, Chief Scientist & DirectorAnna Mowry - Chief Financial OfficerElizabeth Koslosky - Global Investment Research AssociateThomas VonDerVellen - Equity Research Associate Conference Call Participants Jason Lai - Analyst Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter twenty twenty ...

Nautilus Biotechnology (NAUT) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Ji-Yon Yi - Vice PresidentSujal Patel - Co-Founder, CEO & DirectorParag Mallick - Co-Founder, Chief Scientist & DirectorAnna Mowry - Chief Financial OfficerElizabeth Koslosky - Global Investment Research AssociateThomas VonDerVellen - Equity Research Associate Conference Call Participants Jason Lai - Analyst Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter twenty twenty ...